Chromosomal copy number heterogeneity predicts survival rates across cancers

van Dijk, Erik; van den Bosch, Tom; Lenos, Kristiaan J.; El Makrini, Khalid; Nijman, Lisanne E.; van Essen, Hendrik F. B.; Lansu, Nico; Boekhout, Michiel; Hageman, Joris H.; Fitzgerald, Rebecca C.; Punt, Cornelis J. A.; Tuynman, Jurriaan B.; Snippert, Hugo J. G.; Kops, Geert J. P. L.; Medema, Jan Paul; Ylstra, Bauke; Vermeulen, Louis; Miedema, Daniël M.

doi:10.1038/s41467-021-23384-6

Download PDF

Article
Open access
Published: 27 May 2021

Chromosomal copy number heterogeneity predicts survival rates across cancers

Nature Communications volume 12, Article number: 3188 (2021) Cite this article

11k Accesses
33 Citations
14 Altmetric
Metrics details

Subjects

Abstract

Survival rates of cancer patients vary widely within and between malignancies. While genetic aberrations are at the root of all cancers, individual genomic features cannot explain these distinct disease outcomes. In contrast, intra-tumour heterogeneity (ITH) has the potential to elucidate pan-cancer survival rates and the biology that drives cancer prognosis. Unfortunately, a comprehensive and effective framework to measure ITH across cancers is missing. Here, we introduce a scalable measure of chromosomal copy number heterogeneity (CNH) that predicts patient survival across cancers. We show that the level of ITH can be derived from a single-sample copy number profile. Using gene-expression data and live cell imaging we demonstrate that ongoing chromosomal instability underlies the observed heterogeneity. Analysing 11,534 primary cancer samples from 37 different malignancies, we find that copy number heterogeneity can be accurately deduced and predicts cancer survival across tissues of origin and stages of disease. Our results provide a unifying molecular explanation for the different survival rates observed between cancer types.

A pan-cancer compendium of chromosomal instability

Article 15 June 2022

Probability distribution of copy number alterations along the genome: an algorithm to distinguish different tumour profiles

Article Open access 10 September 2020

Signatures of copy number alterations in human cancer

Article Open access 15 June 2022

Introduction

The abundance and diversity of genomic aberrations in cancers is enormous¹. Identifying common characteristics across cancer genomes that define patient survival therefore remains challenging. In particular, malignancies from different cancer types are molecularly highly distinct; therefore, most biomarkers are restricted to a single type of cancer². The hallmark process of genomic instability and its direct consequence ITH are generic features of cancers that might associate with poor prognosis, and could stratify patients and inform on tumour biology in a pan-cancer setting^3,4,5,6.

Genomic instability and intra-tumour heterogeneity (ITH) occur at different levels, ranging from single-nucleotide variations (SNVs) to chromosomal losses and duplications. Most studies of ITH have focused on the single-nucleotide scale, and some reported a relation to survival^{7,8,9,10,11,12}. However, the reliability of these methods based on mutation frequency calling is under debate^13,14,15. In cancers from various organs, it has been shown that chromosomal copy number variations (CNVs) are heterogeneous within tumours^16,17,18,19, and might be more important for patient outcome^18,20. However, a robust and comprehensive method to infer ITH from a single copy number measurement is currently lacking, limiting the possibility to study large numbers of patients in a pan-cancer setting.

Here, we introduce an approach to quantify ITH from a single copy number profile. This method allowed us to uncover that ITH at the copy number level results from ongoing chromosomal instability and underlies cancer prognosis in individual cancer types as well as across distinct malignancies.

Results

Accurate ITH measurement from a single copy number profile: CNH

To derive ITH from a single tissue sample copy number profile, we postulate that each individual cell has strictly integer chromosomal copy numbers (i.e. 0, 1, 2,…). Hence, completely homogeneous samples also have integer copy number values, and deviations from integer values in an absolute copy number profile reflect heterogeneity in the malignant cell population (Fig. 1a). To quantify copy number heterogeneity (CNH) within malignancies, we infer tumour ploidy, sample purity and absolute copy numbers from a normalized and segmented copy number profile^21,22,23. For a range of ploidies (1.5, 1.55,.., 5) and malignant cell purities (0.2, 0.21,.., 1), we calculate the absolute copy number profile, measure the distance of each segment to the closest integer and determine the average distance weighted by segment lengths (see ‘Methods’ for details). CNH is then defined as the minimum of the average weighted distances taken over all ploidies and purities (Fig. 1b).

**Fig. 1: Intra-tumour heterogeneity measurement from single copy number profile.**

CNH can be interpreted as the average fraction of malignant cells that differ by one copy from the mode copy number value at each position of the genome. It integrates the fraction of heterogeneous malignant cells and the fraction of the genome that is heterogeneous in one quantitative score. We verify with single-cell karyotype sequencing, multi-region copy number data and simulated copy number profiles that CNH is accurately determined by our inference procedure (Fig. 1c and Supplementary Fig. 1a–c)^18,24. Non-malignant cells in a cancer sample can affect estimates of ITH¹⁴. We expand our simulations by including increasing fractions of non-malignant cells and find that CNH is robust to varying purities (malignant cell fraction between 0.2 and 1, Fig. 1d). Next, we assess the independence of tumour purity in a dataset containing 253 samples from patients with ovarian cancer, where tumour purity was determined separately from the copy number data²⁵. Inference of CNH using purity as a free parameter (our standard procedure), or fixing purity around the reported value for each sample gives highly concordant results (Supplementary Fig. 1d, e). More generally, multiple combinations of ploidy and purity can result in good fits of absolute copy number profiles, i.e. with small segment distances to integer values (Supplementary Fig. 1f, g). Importantly, CNH is by definition essentially identical for the different solutions (Supplementary Fig. 1h, i). We further note that CNH can be inferred from allele-specific as well as total copy numbers (default), and that filtering of noisy segments can be implemented before the inference of CNH to improve accuracy (Supplementary Figs. 2a–h). Finally, we show that CNH can be accurately determined from stored FFPE material, independent of the measurement platform used to obtain copy number data (Supplementary Fig. 2i). A copy number profile derived from a single sample with unknown cancer cell purity is thus sufficient to accurately determine CNH.

Ongoing chromosomal instability underlies CNH

Does heterogeneity in copy numbers result from ongoing chromosomal instability, or from the coexistence of multiple clones that emerged at some point during cancer evolution^9,24,26,27? Gene-expression profiles can be used as a proxy of chromosomal instability in malignancies²⁸. We explore the relation between chromosomal instability and CNH in an unbiased way using gene expression and copy number data from The Cancer Genome Atlas (TCGA) (8968 patients with copy number and gene-expression data). We determine CNH from the copy number profiles of all primary cancers and correlate CNH to the expression level of all genes (Supplementary Data 1, 2). The correlation of gene-expression levels is close to normally distributed, but the slight enrichment of positive correlations suggests a group of genes related to CNH (Fig. 2a). Indeed, the top genes positively correlated with CNH form a functionally related cluster, including AURKA, a gene encoding a kinase that is targeted to mitotic spindle microtubules by TPX2 in a highly conserved way (Fig. 2b)^29,30,31. Gene ontology analysis of the tail of the distribution (genes with Spearman’s rank correlation >0.42) reveals that high CNH is characterized by chromosomal instability (Fig. 2c and Supplementary Fig. 3a–c)^28,32,33. In contrast, no particular ontology is significantly associated with the most negatively correlated genes. This gene-expression analysis suggests that chromosomal instability drives CNH in a malignancy. Using live imaging of cell divisions in organoids, we find that indeed missegregation of chromosomes is associated with CNH (Supplementary Fig. 3d). While our results indicate that chromosomal instability underlies CNH, we note that other factors also contribute to CNH. For example, we find that haematological malignancies show evidence for high chromosomal instability and low CNH, relative to other cancer types (Supplementary Fig. 3e). The competition between malignant cells in haematological malignancies is less spatially constrained, which facilitates selective sweeps that reduce heterogeneity and could explain the low values of CNH observed in these malignancies³⁴.

**Fig. 2: Chromosomal instability underlies CNH.**

Next, we characterize the relation between CNH and various genomic aberrations. As expected, heterogeneity in copy numbers requires CNVs (Fig. 3a, b)³⁵. Furthermore, we identify mutations in TP53 as most significantly associated with high CNH, suggesting that the ability of a cell to cope with aneuploidy is also vital to CNH (P < 10⁻¹⁵⁰, Fig. 3a, c). TP53 is the most frequently mutated gene across cancers and the safeguard of genome stability, protecting against both CNVs and SNVs³⁵. Indeed, we find that CNH positively correlates with mutational load, except for microsatellite-instable (MSI) tumours in which the correlation is negative (Fig. 3a, d, e). Genome doubling can enhance chromosomal instability³⁶. We find higher CNH for genome-doubled malignancies, which further underlines the relation between CNH and chromosomal instability (Fig. 3a, f).

**Fig. 3: Genetic characterization of CNH.**

CNH is a unifying predictor of survival for cancer patients

Genomic heterogeneity in the malignant cell population is a source for cancer evolution, regardless of the tissue of origin. As cancer evolution impairs patient survival and treatment efficacy, we asked if our CNH measure associates with survival for the different cancer types documented in TCGA³⁷. For each sample, we calculate the CNH and rank-order patients accordingly. We split patients into two groups of equal size for each type of malignancy. We find that CNH distinguishes patients with poor and good prognosis in highly different cancer types, such as uterine corpus endometrial carcinoma (UCEC), acute myeloid leukaemia (LAML), sarcoma (SARC) and brain lower-grade glioma (LGG) (Fig. 4a). For the large majority of cancer types, CNH is associated with poor prognosis for progression-free interval (PFI) and overall survival (OS) (Fig. 4b and Supplementary Figs. 4, 5a).

**Fig. 4: CNH is prognostic for survival in most types of cancer.**

The ITH of the cancer genomes of all patients can be compared on a continuous quantitative scale by CNH. We explored the variation in CNH and survival in a cancer-type agnostic setting, including 10,208 primary cancers with copy number data in TCGA. The median CNH of all cancers is 0.051 and ranges from 0.003 to 0.23 (Fig. 5a). We split patients rank-ordered by the CNH of their primary cancer in five groups of equal size and determine the survival rates for each group. We find that survival rates decrease monotonically with increasing CNH (Fig. 5b). Importantly, we find that it is heterogeneity at the CNV level that determines the poor prognosis, not the mere presence of CNVs (Fig. 5c). CNH also outperforms other measures of ITH (ABSOLUTE ITH³⁸, MATH¹¹, PyClone¹⁰, EXPANDS¹² and S-score¹⁹), as well as the overall amount of CNVs³⁵, in predicting survival across cancers (Supplementary Fig. 6). Hence, CNH accurately predicts survival across cancer types, with a hazard ratio of 2.6 (2.3–3.0) for the 20% patients with the most heterogeneous malignancies compared to the 20% patients with the most homogeneous malignancies (Fig. 5d). Importantly, also in an independent dataset from the International Cancer Genome Consortium (ICGC), we find that CNH explains survival rates across cancers (Fig. 5e, f)¹.

**Fig. 5: CNH predicts pan-cancer survival rates.**

The variation in CNH and the relation to survival might be confounded by other tumour or clinical characteristics, such as cancer type, stage of the disease and MSI status. We address the relation of CNH and survival in the context of these three observables. MSI tumours are thought to be driven by defects in the DNA repair machinery, rather than by chromosomal instability. Nevertheless, also for this molecularly defined subgroup, patients with the most heterogeneous cancers have the poorest prognosis (Fig. 6). For 7972 cancers, the stage is reported in TCGA³⁷. We find that CNH increases with stage (median CNH per stage: stage I, 0.038; stage II, 0.062; stage III, 0.067; stage IV, 0.075; Fig. 7a). The positive correlation between CNH and stage suggests that heterogeneity in copy numbers fosters progression. Nevertheless, within each stage, the survival rates decrease with increasing CNH (Fig. 7b, c), showing that differences in survival rates cannot be explained simply from the stage at diagnosis. Malignancies from different cancer types vary in CNH (Supplementary Fig. 4). Strikingly, the variation in CNH between cancer types correlates to the variation in survival rates of the cancer types (Fig. 8). CNH thus provides a potential molecular explanation for the remarkable differences in survival rates between cancer types. Finally, multivariate analysis, including CNH, aneuploidy score, genome doubling, cancer type, MSI status, stage, age, gender and mutation status of TP53, KRAS, MYC, PTEN, VHL, PIK3CA, APC and BRAF, shows that CNH is a pan-cancer prognostic biomarker for both the PFI and OS (Supplementary Table 1 and Supplementary Fig. 5b–d).

**Fig. 6: Distribution of CNH and survival curves of microsatellite-instable cancers.**

**Fig. 7: CNH increases with stage and is predictive within each stage.**

**Fig. 8: CNH predicts survival rates of cancer types.**

Discussion

The CNH measure introduced here allows direct comparison of all cancer genomes on a quantitative and comprehensive scale. Our analyses of ITH in the pan-cancer TCGA and ICGC cohorts suggest that heterogeneity at the copy number level is a universal predictor for survival of cancer patients, that emerges from ongoing chromosomal instability in interplay with cell intrinsic and external selective pressures.

The ITH of a cancer can be accurately inferred from a single copy number measurement, using the CNH measure introduced in this paper. We extensively validated the accuracy and robustness of our method using simulations, single-cell karyotype sequencing, multi-region CNV data, re-sampling from the same tumour and benchmarking to other ITH methods. However, we note that a possible limitation of single-sample measures is sampling bias³⁹.

Single-sample CNV measurements can be obtained from stored FFPE material at relatively low costs⁴⁰, and we indeed demonstrated that CNH can be successfully inferred from FFPE-derived data. Our method thus has potential to readily translate into the clinic. However, we note that measurements from FFPE material are typically more noisy than measurements from fresh frozen material, and that the survival analyses in the present study are all based on fresh frozen material.

Analyses of gene-expression data and live imaging of cell divisions in organoids revealed that ongoing chromosomal instability importantly contributes to CNH. Ongoing chromosomal instability implies that continuously new karyotypes are generated. Hence, our results suggest that ITH in CNVs cannot be properly understood as, and quantified by, coexistence of a few clones, as has been reported for ITH determined from SNVs^10,12. The relation between ITH in CNVs and ITH in SNVs could be an interesting topic for future studies.

Chromosomal instability has been shown to be a negative predictor of survival in several cancer types²⁸. Aneuploidy, immune escape and inflammation have been proposed as mechanisms through which chromosomal instability results in poor prognosis^20,41. Our results provide an alternative explanation: chromosomal instability generates genomic diversity in the malignant cell population on which natural selection acts.

Although we find an important relation between CNH and chromosomal instability, we stress that these are not identical observables. Chromosomal instability is a process at the cell level; CNH is a state at the level of the malignant cell population. While chromosomal instability increases ITH, other cell intrinsic and external selective pressures can reduce the heterogeneity, e.g. differences in fitness between malignant cells and immune suppression. Further understanding of the relation between CNH, selection and chromosomal instability might be obtained by sampling at multiple time points and interpreting the results with evolutionary models. For example, in a recent publication by Minussi et al., it was concluded from extensive karyotyping of single cells from triple-negative breast cancers combined with mathematical modelling, that ongoing chromosomal instability persists during expansion of primary cancers⁴², in line with our conclusions.

CNH increases with stage, stratifies patients for survival within most cancer types and across molecular subgroups and explains why some cancer types have a dismal prognosis compared to other cancer types. The covariance of CNH with stage, and also grade, reduces the independent predictive value of CNH in multivariate analyses. On the other hand, the covariance of CNH with stage and survival implies that progression of disease can be assessed from the molecular properties of the primary cancer. CNH could thus provide a unifying molecular explanation for variations in survival time of patients, from a cancer evolution perspective.

Methods

Data sets

TCGA—Segmented copy number data, gene-expression data, mutation data and MSI data of TCGA were downloaded from http://gdac.broadinstitute.org/. In all analyses, only samples from a primary tumour or a primary blood-derived cancer were included (n = 10,578 with copy number data). We applied noise filtering based on segment noise (described below), filtering out 370 samples (n = 10,208 that pass quality control).

The copy number data from the ‘genome_wide_snp_6-segmented_scna_hg19’ files were used. The MSI status of each sample was obtained from the ‘patient.microsatellite_instability_test_results.microsatellite_instability_test_result.mononucleotide_and_dinucleotide_marker_panel_analysis_status’ variable from the ‘Merge_Clinical’ data files. For the gene-expression data, the RSEM from the ‘illuminahiseq_rnaseqv2-RSEM_genes’ files was used. Mutation data were obtained from the ‘Mutation_Packager_Oncotated_Calls.Level_3’ files. Mutations annotated as SNPs in columns ‘dbSNP_Val_Status’ and as Silent in columns ‘Variant_Classification’ were excluded.

Tangent-normalized probe copy numbers and raw SNP probe data were downloaded from https://portal.gdc.cancer.gov/legacy-archive. Probe intensities from .CEL raw data files of SARC, UCEC, LGG and LAML were processed using Affymetrix Power Tools and allele-specific copy numbers were calculated using HAPSEG (version 1.1.1) and ABSOLUTE (version 1.0.6).

Genome doubling, aneuploidy score and mutational load, and ploidy, purity and ITH, as determined by ABSOLUTE using copy number and mutation data, were obtained from Thorsson et al.³⁸. Patient progression and survival times, disease stages, grade of disease, age and gender were obtained from Liu et al.³⁷. Chromothripsis determined per chromosome from whole-genome sequencing was obtained of 759 TCGA patients from Cortes-Ciriano et al.⁴³.

BriTROC-1—The ovarian cancer dataset was obtained from the corresponding author and contains 253 primary and relapsed ovarian cancer samples from 132 patients in the British Translational Research Ovarian Cancer Collaborative (BriTROC-1) cohort²⁵ (Supplementary Fig. 1d, e).

TRACERx—The multi-region non-small-cell lung cancer data from TRACERx consist of 303 samples from 100 patients and the copy number data were obtained from Jamal-Hanjani et al.¹⁸ (Supplementary Fig. 1a).

CAIRO2—Copy-number data of 96 patients from the CAIRO2 trial⁴⁴ were measured with arrayCGH by Haan et al.⁴⁵ (available from expression omnibus (GEO), accession code GSE36864) and shallow–whole-genome sequencing by Smeets et al.⁴⁶ (available from EGA, accession code EGAS00001002617). We used these data for technical validation of our method (Supplementary Fig. 2i).

Single cells—Single-cell karyotype sequencing of seven samples from colorectal cancer (CRC) patients was performed²⁴. Acquisition of patient samples was conducted in accordance with the Declaration of Helsinki with the approval of the Amsterdam UMC, VU University Medical Ethical Testing Committee (2016.254-NL57226.029.16 and 2017-302(A2018)). All patients provided written informed consent. In addition, single-cell data from four CRC samples and 12 healthy colon and CRC-derived organoids were obtained from Bolhaquiero et al.²⁴.

Organoids for live imaging—Imaging of four oesophageal cancer-derived organoid lines (CAM277, CAM408, CAM479 and CAM486) and two ovarian cancer-derived organoid lines (HGS-1 and HGS-3.1) was performed as described previously²⁴. Briefly, the percentage of cell divisions with chromosomal missegregation was recorded following overnight time-lapse imaging of organoids expressing H2B-Dendra. Genomic DNA was isolated from each organoid line and measured with Illumina SNP chips GSA v3. GenomeStudio was used with standard settings to obtain copy numbers from the SNP data. In addition, live-imaging data of 12 CRC and normal intestinal organoid lines, with the corresponding single-cell karyotype sequencing data to calculate CNH, were obtained from Bolhaquiero et al.²⁴ (Supplementary Fig. 3d).

ICGC—Processed copy number somatic mutation data files were downloaded to the Collaboratory cancer cloud. Segmented copy number values were obtained from the ‘TCNExact’ variable. Cancer types were defined according to ICGC project code. Patient OS data were obtained from the ICGC data portal: https://dcc.icgc.org/releases/PCAWG/clinical_and_histology. Variables ‘donor_survival_time’ (OS) and ‘donor_vital_status’ (censoring) from the file ‘pcawg_donor_clinical_August2016_v9.xlsx’ were used. A total of 1326 patients from 19 studies had copy number and survival data, and were not part of TCGA (Figs. 5e, f and 8c).

PyClone and EXPANDS—Single-sample measurements of ITH by PyClone¹⁰ and EXPANDS¹² of 1152 and 1095 primary cancers, respectively, of pan-cancer TCGA data, were obtained from Andor et al.⁹.

Copy-number heterogeneity (CNH)

Input—CNH is calculated from a single segmented whole-genome copy number profile. The copy number data must have been obtained from a bulk sample, i.e. not from a single cell.

Calculation—The segmented copy number profile is first normalized by dividing through the mean copy number. The resulting relative copy number ${r}_{i}$ of segment $i$ with width ${w}_{i}$ depends on the absolute copy number ${q}_{i}$ of segment $i$, on the average sample ploidy$\,\tau\!\!:$

$$\tau =\frac{\mathop{\sum}\limits_{i}{w}_{i}{q}_{i}}{\mathop{\sum}\limits_{i}{w}_{i}}$$

(1)

and on the purity of malignant cells in the sample $\alpha$:

$${r}_{i}=\frac{\alpha {q}_{i}+2(1-\alpha )}{\alpha \tau +2(1-\alpha )}$$

(2)

To derive the CNH from the measured relative copy numbers using this expression, we note that ${q}_{i}$ are integers for samples without heterogeneity, and deviations from integer values ${d}_{i}\!\!:$

$${{d}_{i}={\rm{|}}q}_{i}-{{\mathrm{round}}}\left({q}_{i}\right){\rm{|}}$$

(3)

reflect heterogeneity in the sample. The rationale to find the CNH is hence minimization of the deviations of ${q}_{i}$ from integer values:

$${{\mathrm{CNH}}}={{\min }}_{\alpha ,\tau }\left(\frac{\mathop{\sum}\limits_{i}{d}_{i}{w}_{i}}{\mathop{\sum}\limits_{i}{w}_{i}}\right)$$

(4)

Minimization over tumour purity and ploidy is done as these are typically unknown sample properties. Using the experimentally obtained relative copy numbers ${r}_{i}$ and varying tumour purity ($\alpha =0.2, 0.21,\ldots, 1$) and tumour ploidy ($\tau =1.5, 1.55, \ldots, 5$) over biologically relevant ranges, one finds the CNH of a sample by solving Eqs. (1–4).

Samples with known purity or ploidy—A sample’s purity or ploidy can be (approximately) known from independent measurements. In that case, minimization in Eq. (4) might be restricted to a specific range or fixed value for each sample to find CNH. For example, in the analysis of the Ovarian cancer dataset, we restricted the purity to a narrow range of 10% around the reported purity for each sample (Supplementary Fig. 1d, e). The ploidy and purity determined by ABSOLUTE were used to calculate ‘CNH ABSOLUTE’ (Supplementary Fig. 6a, c).

Robustness of inference—Inference of CNH can be performed, also if a sample contains no or few CNVs. With few CNVs, a low value of CNH will be found (Supplementary Fig. 3b). Furthermore, noise in the CNV data affects CNH, but the inference can be optimized to handle noise as detailed below and in Supplementary Fig. 2. Only if all CNVs occur at the same frequency, a scenario we did not come across, the inference is not applicable. CNH is designed as a genome-wide measure. Although segments of the genome that are subject to high noise can be excluded, in general, we recommend against applying the CNH method to single genomic segments or chromosome arms.

Invariance of CNH—CNH is defined as the average segment distance to integer values of the absolute copy number profile. A translation of the absolute copy number profile by an integer value hence leaves CNH invariant. Changing the ploidy by an integer value and adjusting the purity accordingly (purity_new = −2/ploidy_new + purity_inferred + 2/ploidy_inferred) approximately results in translation of the copy number profile by an integer value. Indeed, CNH is highly correlated to the CNH calculated from the inferred ploidy +/−1 in TCGA data (Supplementary Fig. 1f–i). In these analyses, ploidy is fixed to +/−1 the inferred ploidy, and for the samples for which the transferred ploidy is within the limits we consider biologically relevant ($1.5\le \tau \le 5$) a grid search is done for purity, and the corresponding CNH is reported (n = 1884 for ploidy +1; n = 4454 for ploidy −1).

Noise filtering—CNH is inferred by default from genome-wide copy number data. It is possible to exclude certain regions of the genome (segments) from the CNH inference, e.g. if local noise is high. The precision at which the copy number value of a segment can be estimated is quantified by the standard deviation of the mean (σ_μ) of the distribution of probe/bin copy number values around a copy number segment (Supplementary Fig. 2a). Noise filtering can be applied per segment and on the mean σ_μ of a sample. For the TCGA data, we filtered out samples with 〈σ_μ〉 > 0.006 (removing the 370 noisiest samples; average is weighted by segment length) and segments with σ_μ > 0.01 (removing the noisiest segments, composing on average 3.5% of the genome; Supplementary Fig. 2b–f).

Simulations

Computer simulations were developed to verify the accuracy of the CNH measurement. In these simulations, a malignancy with input CNH h is simulated as a collection of 10⁹ cells. The karyotype of the cells in the malignancy is simulated by the following procedure:

(1)
The segments, with possibly different numbers of copies that together comprise the genome of malignant cells, are either taken from a random sample in the TCGA with a genome fraction altered of more than 50% (Fig. 1d and Supplementary Fig. 1b) or generated as n segments of random length (Supplementary Fig. 1c).
(2)
All malignant cells are first given the same number of copies of each segment (a homogeneous sample).
(3)
Heterogeneity is introduced by changing the number of copies of each segment randomly by plus or minus one in a fraction f of the malignant cells. For each segment, f is a random number drawn from a flat distribution between 0 and 2*h, such that $\left\langle f\right\rangle =h$.
(4)
To include non-malignant cells in impure tumour samples, a fraction 1 − α of the malignant cells is replaced by non-malignant cells with a diploid genome.

The average karyotype of the cells in the malignancy is determined and used to infer CNH. For each purity and input heterogeneity, 100 malignancies were simulated and CNH was measured. We find an excellent agreement between the simulated input heterogeneity h and the measured CNH of the simulated malignancies.

Gene expression and CNH

For n = 9198 samples of primary cancers, copy number and gene-expression data were both available in TCGA (n = 8968 after noise filtering). The expression level of each gene was correlated to CNH using Spearman’s rank correlation. The correlation is done in a pan-cancer setting, and we note that gene-expression patterns vary between cancer types. In total, 18,021 genes were significantly correlated with CNH (P < 0.05). The distribution of Spearman’s ρ of all genes, however, forms an almost normal distribution (mean = 0.024; 95% confidence interval of mean = 0.022–0.027; standard deviation = 0.1523; 95% confidence interval of standard deviation = 0.1508–0.1513 for the Gaussian fit in Fig. 2a). For the gene ontology analysis, we therefore focused on the genes most positively correlated with CNH in the tail of the distribution (104 genes with ρ > 0.42). To determine the gene ontologies associated with negative correlation to CNH on the same number of genes, we selected the 104 most negatively correlated genes. Gene ontologies were determined for all GO terms using the ‘Statistical overrepresentation test’ of PANTHER (http://www.pantherdb.org/; Fig. 2c and Supplementary Fig. 3c)^32,33.

Chromosomal instability was assessed in each malignancy by the CIN70 signature²⁸. The expression of the genes that comprise this signature was normalized per gene by the median expression and summed per malignancy to arrive at the CIN70 score for each malignancy (Supplementary Fig. 3e).

Gene network analysis for co-functionality of genes was performed using GADO³¹. We constructed a list of 100 genes, containing the 20 genes most positively correlated with CNH and 80 randomly picked genes, and used the ‘Function Enrichment’ option in the online tool (https://www.genenetwork.nl/) to build the network in Fig. 2b (genes used for co-functionality analysis are indicated in the source data of Fig. 2). The edge threshold in the network (Z-score, representing significance in terms of the number of standard deviations and is equivalent to P value) was set to maximum co-functionality (Z-score > 13.22). The network in Fig. 2b only contains genes positively correlated to CNH. The Z-score can be lowered to 7.06 before this network will contain any of the randomly picked genes.

Genomic aberrations and CNH

The aneuploidy score quantifies the number of chromosome arms that deviate from diploid and was correlated to CNH using Spearman’s rank correlation (Supplementary Fig. 3a, b)³⁵. Genome doubling and mutational load in TCGA data were obtained from Thorsson et al.³⁸, and the relation to CNH was assessed by the Wilcoxon’s rank-sum test (Fig. 3a, f) and Spearman’s rank correlation (Fig. 3a, d, e), respectively. The genome fraction altered was defined as the fraction of the genome subject to CNVs. A segment was considered altered if log(r) ≤ −0.1 (loss) or log(r) ≥ 0.1 (gain).

For n = 9656 samples of primary cancers, copy number and mutation data were both available in TCGA (n = 9388 after noise filtering). For all genes, samples were grouped as either wild type or mutated. The distributions of CNH between the wild-type and mutated groups were compared using the Wilcoxon rank-sum test.

Validation of CNH with single-cell data

Single-cell data were generated as described in, and obtained from, Bolhaquiero et al.²⁴. Briefly, tissue cuts were lysed in a nuclei Suspension Buffer and stained with 10 μg ml⁻¹ Hoechst 34580 (Sigma-Aldrich). The lysed tissue was kept on ice for 1 h after which it was filtered through 70- and 35-μm strainers. Nuclei were sorted on a DB FACS Fusion sorting for G1 state in a 384-well plate containing 5 μl of mineral oil (Sigma) in each well, and stored at −20 °C until further processing for library preparation and sequencing. Library preparation started with a Prot K (Fisher) treatment, after which the genomic DNA was digested with NlaIII restriction enzyme. A cell-specific 8-bp barcode, a 3-bp random molecular barcode, the 5′ Illumina TruSeq small RNA kit adapter and a T7 promoter was ligated. DNA of each cell was pooled and in vitro-transcribed after which it was fragmented and reverse-transcribed, converted to double-stranded cDNA and amplified with PCR. Illumina sequencing libraries were prepared with the TruSeq small RNA primers (Illumina). Libraries were sequenced on an Illumina Nextseq 500 with 75-bp single-end sequencing.

Sequencing reads were aligned to genome build ‘GRCh38.p10’ with bwa (v0.7.12). Quality control was performed with Aneufinder v1.14 with default parameters and as described previously. In addition, cells with reads <20,000 and spikiness >0.25 were excluded. We generate a quasi-bulk copy number by taking an equal amount of reads from each cell for each sample. Quasi-bulk copy number profiles were generated from the pooled reads using QDNAseq⁴⁰. From the quasi-bulk copy number profiles CNH was inferred. Next, we calculate single-cell CNH directly from the single-cell karyotypes (absolute copy numbers) of each sample as follows. We find the minimum consecutive set of segments that comprise the genome of all single cells of a sample. For each segment, we determine the most frequent absolute integer copy number in the sample, and define the local heterogeneity as the fraction of cells that have a value different than the most frequent value. CNH quantified directly from single cells is then defined as the average heterogeneity across segments, weighted by segment lengths and correlated to CNH from quasi-bulk analysis using Spearman’s rank correlation (Fig. 1c).

Validation of CNH with multi-region data

A multi-region copy number dataset containing 303 samples from 100 patients was obtained from Jamal-Hanjani et al.¹⁸. All 303 samples in this dataset are bulk samples, i.e. consisting of more than one malignant cell. Hence, CNH can be inferred from the copy number data of each single sample and averaged over all samples from a patient to arrive at an estimate of CNH per patient. In addition, we calculate multi-region CNH from copy number profiles from the different regions of a patient as follows. We find the minimum consecutive set of segments that comprise the genome of all regions measured from a patient. For each segment, we determine the most frequent absolute integer (rounded) copy number in the sample, and define the local heterogeneity as the fraction of regions that have a (rounded) copy number value different than the most frequent value. The multi-region CNH is then defined as the average heterogeneity across segments, weighted by segment lengths. The average CNH of all regions from a patient was correlated to the multi-region CNH using Spearman’s rank correlation (Supplementary Fig. 1a).

Comparison of CNH to other ITH measures

We compare CNH to other single-sample ITH measures on TCGA data. We obtain ITH according to PyClone (n = 1095 primary cancers) and EXPANDS (n = 1152 primary cancers) from Andor et al.⁹ and ITH according to ABSOLUTE applied to copy number and mutation data (n = 9399 primary cancers) from Thorsson et al.³⁸. These three methods use both copy number and mutation data to infer ITH. We calculate S-score¹⁹ from the copy number data of 10,379 primary cancers and MATH¹¹ from the mutation data of 9290 primary cancers. In addition, we calculate ITH using ABSOLUTE applied to copy number data only for SARC, LAML, UCEC and LGG (1255 primary cancers). For each of these measures, and CNH, we calculate the concordance-index for predicting OS using the ‘survival’ R package (v3.2.7) and the ‘compareC’ R package (v1.3.1). We find that CNH is significantly better in predicting survival than any of the other methods considered. ABSOLUTE ITH quantifies the fraction of the genome that is sub-clonal, and is therefore the ITH method conceptually most similar to CNH. We correlate each of the ITH measures, including CNH, to ABSOLUTE ITH and find that indeed CNH correlates strongly (and better than the other methods) to ABSOLUTE ITH. We note that performance of ABSOLUTE to measure ITH depends on both CNV and mutation data. Indeed, we find a drop in performance of ABSOLUTE when applied to CNV data only (ABSOLUTE ITH without mutation data has a C-index = 0.53 when applied to data from SARC, LAML, UCEC and LGG. ABSOLUTE ITH, including mutation, has a C-index = 0.55 applied to the same data, and C-index = 0.58 when applied to all data in TCGA). Accurate prediction of ITH by ABSOLUTE hence depends on both CNV and SNV data (Supplementary Fig. 6).

Statistical analyses and software

The statistical tests used were reported with each analysis and all tests were two-sided. HapSeg (v1.1.1) and ABSOLUTE (v1.0.6) were used to analyze SNParray data. BWA (v0.7.12) was used for read alignment of single-cell data and R-package Aneufinder (v1.14) was used to further analyze single-cell data. Cox proportional-hazard models were constructed with the ‘coxph’ function from the ‘survival’ package (v 3.2.7) and Concordance-indices were determined and compared using ‘CompareC’ function from the ‘CompareC’ package (v1.3.1)⁴⁷. R-version used was R-3.6.3. All other analyses were performed in, and all code was written in MATLAB R2019a.

Reporting summary

Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability

TCGA data analyzed in this paper can be downloaded from http://gdac.broadinstitute.org. The BriTROC-1 data are available on: https://bitbucket.org/britroc/cnsignatures/src/master/ and raw data can be obtained by contacting James Brenton, corresponding author of the original publication: James.Brenton@cruk.cam.ac.uk. CAIRO2 data measured with arrayCGH are publicly available from gene-expression omnibus (GEO), accession code GSE36864, and shallow–whole-genome sequencing is available from the European Genome Archive (EGA), accession code EGAS00001002617. Data from TRACERX used in this study are available from Supplementary Appendix 2 of Jamal-Hanjani et al.¹⁸. Data from ICGC are under restricted access, available from https://dcc.icgc.org/repositories.

Data generated in this study: single-cell karyotype of CRC samples and SNP data measured from bulk of the oesophageal and ovarian organoids are available from the EGA, under accession number EGAS00001004702. Source data are provided with this paper.

Code availability

MATLAB code to calculate CNH from a segmented copy number profile is available here: https://github.com/dmmiedema/CNH.

References

The ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. Pan-cancer analysis of whole genomes. Nature 578, 82–93, https://doi.org/10.1038/s41586-020-1969-6 (2020).
Haigis, K. M., Cichowski, K. & Elledge, S. J. Tissue-specificity in cancer: the rule, not the exception. Science 363, 1150–1151 (2019).
Article ADS CAS Google Scholar
Marusyk, A., Janiszewska, M. & Polyak, K. Intratumor heterogeneity: the Rosetta stone of therapy resistance. Cancer Cell 37, 471–484 (2020).
Article CAS Google Scholar
McGranahan, N. & Swanton, C. Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer Cell 27, 15–26 (2015).
Article CAS Google Scholar
Reiter, J. G. et al. An analysis of genetic heterogeneity in untreated cancers. Nat. Rev. Cancer 19, 639–650 (2019).
Article CAS Google Scholar
Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).
CAS PubMed Google Scholar
Salcedo, A. et al. A community effort to create standards for evaluating tumor subclonal reconstruction. Nat. Biotechnol. 38, 97–107 (2020).
Article CAS Google Scholar
Morris, L. G. et al. Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival. Oncotarget 7, 10051–10063 (2016).
Article Google Scholar
Andor, N. et al. Pan-cancer analysis of the extent and consequences of intratumor heterogeneity. Nat. Med. 22, 105–113 (2016).
Article CAS Google Scholar
Roth, A. et al. PyClone: statistical inference of clonal population structure in cancer. Nat. Methods 11, 396–398 (2014).
Article CAS Google Scholar
Mroz, E. A. & Rocco, J. W. MATH, a novel measure of intratumor genetic heterogeneity, is high in poor-outcome classes of head and neck squamous cell carcinoma. Oral. Oncol. 49, 211–215 (2013).
Article CAS Google Scholar
Andor, N., Harness, J. V., Muller, S., Mewes, H. W. & Petritsch, C. EXPANDS: expanding ploidy and allele frequency on nested subpopulations. Bioinformatics 30, 50–60 (2014).
Article CAS Google Scholar
Noorbakhsh, J., Kim, H., Namburi, S. & Chuang, J. H. Distribution-based measures of tumor heterogeneity are sensitive to mutation calling and lack strong clinical predictive power. Sci. Rep. 8, 11445 (2018).
Article ADS Google Scholar
Abecassis, J. et al. Assessing reliability of intra-tumor heterogeneity estimates from single sample whole exome sequencing data. PLoS ONE 14, e0224143 (2019).
Article CAS Google Scholar
Shi, W. et al. Reliability of whole-exome sequencing for assessing intratumor genetic heterogeneity. Cell Rep. 25, 1446–1457 (2018).
Article CAS Google Scholar
Mamlouk, S. et al. DNA copy number changes define spatial patterns of heterogeneity in colorectal cancer. Nat. Commun. 8, 14093 (2017).
Article ADS CAS Google Scholar
Navin, N. et al. Tumour evolution inferred by single-cell sequencing. Nature 472, 90–94 (2011).
Article ADS CAS Google Scholar
Jamal-Hanjani, M. et al. Tracking the evolution of non-small-cell lung cancer. N. Engl. J. Med. 376, 2109–2121 (2017).
Article CAS Google Scholar
Martinez, P. et al. Quantification of within-sample genetic heterogeneity from SNP-array data. Sci. Rep. 7, 3248 (2017).
Article ADS Google Scholar
Davoli, T., Uno, H., Wooten, E. C. & Elledge, S. J. Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. Science 355, https://doi.org/10.1126/science.aaf8399 (2017).
Poell, J. B. et al. ACE: absolute copy number estimation from low-coverage whole-genome sequencing data. Bioinformatics 35, 2847–2849 (2019).
Article CAS Google Scholar
Carter, S. L. et al. Absolute quantification of somatic DNA alterations in human cancer. Nat. Biotechnol. 30, 413–421 (2012).
Article CAS Google Scholar
Van Loo, P. et al. Allele-specific copy number analysis of tumors. Proc. Natl Acad. Sci. U S A 107, 16910–16915 (2010).
Article ADS Google Scholar
Bolhaqueiro, A. C. F. et al. Ongoing chromosomal instability and karyotype evolution in human colorectal cancer organoids. Nat. Genet. 51, 824–834 (2019).
Article CAS Google Scholar
Macintyre, G. et al. Copy number signatures and mutational processes in ovarian carcinoma. Nat. Genet. 50, 1262–1270 (2018).
Article CAS Google Scholar
Bakhoum, S. F. & Landau, D. A. Chromosomal instability as a driver of tumor heterogeneity and evolution. Cold Spring Harb. Perspect. Med. 7, https://doi.org/10.1101/cshperspect.a029611 (2017).
Watkins, T. B. K. et al. Pervasive chromosomal instability and karyotype order in tumour evolution. Nature https://doi.org/10.1038/s41586-020-2698-6 (2020).
Carter, S. L., Eklund, A. C., Kohane, I. S., Harris, L. N. & Szallasi, Z. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat. Genet. 38, 1043–1048 (2006).
Article CAS Google Scholar
Hadzipasic, A. et al. Ancient origins of allosteric activation in a Ser-Thr kinase. Science 367, 912–917 (2020).
Article ADS CAS Google Scholar
van Gijn, S. E. et al. TPX2/Aurora kinase A signaling as a potential therapeutic target in genomically unstable cancer cells. Oncogene 38, 852–867 (2019).
Article Google Scholar
Deelen, P. et al. Improving the diagnostic yield of exome- sequencing by predicting gene-phenotype associations using large-scale gene expression analysis. Nat. Commun. 10, 2837 (2019).
Article ADS Google Scholar
Thomas, P. D. et al. PANTHER: a library of protein families and subfamilies indexed by function. Genome Res. 13, 2129–2141 (2003).
Article CAS Google Scholar
Thomas, P. D. et al. Applications for protein sequence-function evolution data: mRNA/protein expression analysis and coding SNP scoring tools. Nucleic Acids Res. 34, W645–W650 (2006).
Article ADS Google Scholar
Fusco, D., Gralka, M., Kayser, J., Anderson, A. & Hallatschek, O. Excess of mutational jackpot events in expanding populations revealed by spatial Luria-Delbruck experiments. Nat. Commun. 7, 12760 (2016).
Article ADS CAS Google Scholar
Taylor, A. M. et al. Genomic and functional approaches to understanding cancer aneuploidy. Cancer Cell 33, 676–689.e3 (2018).
Article CAS Google Scholar
Dewhurst, S. M. et al. Tolerance of whole-genome doubling propagates chromosomal instability and accelerates cancer genome evolution. Cancer Discov. 4, 175–185 (2014).
Article CAS Google Scholar
Liu, J. et al. An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell 173, 400–416.e11 (2018).
Article CAS Google Scholar
Thorsson, V. et al. The immune landscape of cancer. Immunity 48, 812–830.e14 (2018).
Article CAS Google Scholar
Litchfield, K. et al. Representative sequencing: unbiased sampling of solid tumor tissue. Cell Rep. 31, 107550 (2020).
Article CAS Google Scholar
Scheinin, I. et al. DNA copy number analysis of fresh and formalin-fixed specimens by shallow whole-genome sequencing with identification and exclusion of problematic regions in the genome assembly. Genome Res. 24, 2022–2032 (2014).
Article CAS Google Scholar
Bakhoum, S. F. et al. Chromosomal instability drives metastasis through a cytosolic DNA response. Nature 553, 467–472 (2018).
Article ADS CAS Google Scholar
Minussi, D. C. et al. Breast tumours maintain a reservoir of subclonal diversity during expansion. Nature https://doi.org/10.1038/s41586-021-03357-x (2021).
Cortes-Ciriano, I. et al. Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing. Nat. Genet. 52, 331–341 (2020).
Article CAS Google Scholar
Tol, J. et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N. Engl. J. Med. 360, 563–572 (2009).
Article CAS Google Scholar
Haan, J. C. et al. Genomic landscape of metastatic colorectal cancer. Nat. Commun. 5, 5457 (2014).
Article ADS CAS Google Scholar
Smeets, D. et al. Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy. Nat. Commun. 9, 4112 (2018).
Article ADS Google Scholar
Kang, L., Chen, W., Petrick, N. A. & Gallas, B. D. Comparing two correlated C indices with right-censored survival outcome: a one-shot nonparametric approach. Stat. Med. 34, 685–703 (2015).
Article MathSciNet Google Scholar

Download references

Acknowledgements

This work was supported by Amsterdam UMC and Oncode, by CRUK and MRC for the development and characterization of organoids, by a KWF and an intramural grant of the Pathology department of Amsterdam UMC to B.Y., by a talent development grant of the AG&M institute of Amsterdam UMC and a Young Investigator Grant of KWF to D.M.M.; L.V. is a New York Stem Cell Foundation—Robertson Investigator. We thank The Cancer Genome Atlas, the International Cancer Genome Consortium, the TRACERx consortium and J. Brenton for providing data.

Author information

These authors contributed equally: Erik van Dijk, Tom van den Bosch.

Authors and Affiliations

Department of Pathology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
Erik van Dijk, Hendrik F. B. van Essen & Bauke Ylstra
LEXOR, Center for Experimental and Molecular Medicine, Cancer Center Amsterdam and Amsterdam Gastroenterology & Metabolism, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
Tom van den Bosch, Kristiaan J. Lenos, Khalid El Makrini, Lisanne E. Nijman, Jan Paul Medema, Louis Vermeulen & Daniël M. Miedema
Oncode Institute, Amsterdam, The Netherlands
Tom van den Bosch, Kristiaan J. Lenos, Khalid El Makrini, Lisanne E. Nijman, Nico Lansu, Michiel Boekhout, Joris H. Hageman, Hugo J. G. Snippert, Geert J. P. L. Kops, Jan Paul Medema, Louis Vermeulen & Daniël M. Miedema
Hubrecht institute—KNAW and University Medical Center Utrecht, Utrecht, The Netherlands
Nico Lansu & Geert J. P. L. Kops
Center for Molecular Medicine, University Medical Centre Utrecht, Utrecht, The Netherlands
Michiel Boekhout, Joris H. Hageman & Hugo J. G. Snippert
MRC Cancer Unit, University of Cambridge, Cambridge, UK
Rebecca C. Fitzgerald
Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands
Cornelis J. A. Punt
Department of Surgery, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
Jurriaan B. Tuynman

Authors

Erik van Dijk
View author publications
You can also search for this author in PubMed Google Scholar
Tom van den Bosch
View author publications
You can also search for this author in PubMed Google Scholar
Kristiaan J. Lenos
View author publications
You can also search for this author in PubMed Google Scholar
Khalid El Makrini
View author publications
You can also search for this author in PubMed Google Scholar
Lisanne E. Nijman
View author publications
You can also search for this author in PubMed Google Scholar
Hendrik F. B. van Essen
View author publications
You can also search for this author in PubMed Google Scholar
Nico Lansu
View author publications
You can also search for this author in PubMed Google Scholar
Michiel Boekhout
View author publications
You can also search for this author in PubMed Google Scholar
Joris H. Hageman
View author publications
You can also search for this author in PubMed Google Scholar
Rebecca C. Fitzgerald
View author publications
You can also search for this author in PubMed Google Scholar
Cornelis J. A. Punt
View author publications
You can also search for this author in PubMed Google Scholar
Jurriaan B. Tuynman
View author publications
You can also search for this author in PubMed Google Scholar
Hugo J. G. Snippert
View author publications
You can also search for this author in PubMed Google Scholar
Geert J. P. L. Kops
View author publications
You can also search for this author in PubMed Google Scholar
Jan Paul Medema
View author publications
You can also search for this author in PubMed Google Scholar
Bauke Ylstra
View author publications
You can also search for this author in PubMed Google Scholar
Louis Vermeulen
View author publications
You can also search for this author in PubMed Google Scholar
Daniël M. Miedema
View author publications
You can also search for this author in PubMed Google Scholar

Contributions

E.v.D., T.v.d.B., K.J.L., H.J.G.S., G.J.P.L.K., J.P.M., B.Y., L.V. and D.M.M. analyzed data; M.B. and J.H.H. performed live imaging of organoids. N.L. performed single-cell karyotype experiments. K.E.M., L.E.N. and H.F.B.v.E. supported lab work. R.C.F., C.J.A.P. and J.B.T. contributed samples. E.v.D., L.V. and D.M.M. wrote the paper; D.M.M. designed and directed the research.

Corresponding authors

Correspondence to Louis Vermeulen or Daniël M. Miedema.

Ethics declarations

Competing interests

E.v.D., B.Y., L.V. and D.M.M. are listed as inventors in a pending patent application (NL82151) filed by Oncode Institute on behalf of the Academisch Medisch Centrum, covering the content of the paper. The remaining authors declare no competing interests.

Additional information

Peer review information Nature Communications thanks the anonymous reviewers for their contribution to the peer review of this work. Peer reviewer reports are available.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Supplementary Information

Peer Review File

Description of Additional Supplementary Files

Supplementary Data 1

Supplementary Data 2

Reporting Summary

Source data

Source Data

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Cite this article

van Dijk, E., van den Bosch, T., Lenos, K.J. et al. Chromosomal copy number heterogeneity predicts survival rates across cancers. Nat Commun 12, 3188 (2021). https://doi.org/10.1038/s41467-021-23384-6

Download citation

Received: 10 February 2021
Accepted: 14 April 2021
Published: 27 May 2021
DOI: https://doi.org/10.1038/s41467-021-23384-6

This article is cited by

The two sides of chromosomal instability: drivers and brakes in cancer
- Rendy Hosea
- Sharon Hillary
- Vivi Kasim
Signal Transduction and Targeted Therapy (2024)
Aneuploidy and complex genomic rearrangements in cancer evolution
- Toby M. Baker
- Sara Waise
- Peter Van Loo
Nature Cancer (2024)
Genetic heterogeneity in p53-null leukemia increases transiently with spindle assembly checkpoint inhibition and is not rescued by p53
- Mai Wang
- Steven Phan
- Dennis E. Discher
Chromosoma (2024)
Systematic in vitro analysis of therapy resistance in glioblastoma cell lines by integration of clonogenic survival data with multi-level molecular data
- Leon Emanuel Schnöller
- Daniel Piehlmaier
- Michael Orth
Radiation Oncology (2023)
The copy number and mutational landscape of recurrent ovarian high-grade serous carcinoma
- Philip Smith
- Thomas Bradley
- Iain A. McNeish
Nature Communications (2023)

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.